Market Performance - The medical beauty sector rose by 2.11% on September 11, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 3875.31, up 1.65%, while the Shenzhen Component Index closed at 12979.89, up 3.36% [1] Individual Stock Performance - Ai Meike (300896) closed at 201.00, with a gain of 3.10% and a trading volume of 46,300 shares, amounting to a transaction value of 909 million yuan [1] - Huaxi Biological (688363) closed at 59.51, up 0.86%, with a trading volume of 47,500 shares, totaling 279 million yuan [1] - ST Meigu (000615) remained unchanged at 3.14, with a trading volume of 55,800 shares, amounting to 17.45 million yuan [1] - Jinbo Biological (832982) closed at 307.80, down 0.03%, with a trading volume of 7,759.81 shares, totaling 237 million yuan [1] Capital Flow Analysis - The medical beauty sector saw a net inflow of 35.23 million yuan from institutional investors, while retail investors experienced a net outflow of 45.10 million yuan [1] - Ai Meike had a net inflow of 35.43 million yuan from institutional investors, but a net outflow of 40.20 million yuan from retail investors [2] - Huaxi Biological experienced a net inflow of 1.46 million yuan from institutional investors, with a net outflow of 6.54 million yuan from retail investors [2] - ST Meigu had a net outflow of 1.66 million yuan from institutional investors, but a net inflow of 1.64 million yuan from retail investors [2]

Market Overview - The Shanghai Composite Index closed at 3819.32 points, with a gain of 0.32%, and the total trading volume of A-shares reached 1,641.14 billion yuan [1] - As of the current date, 29 A-shares have surpassed their annual moving average, indicating positive market sentiment [1] Notable Stocks - The stocks with the highest deviation rates from their annual moving average include: - Luopuskin (002333) with a deviation rate of 8.13% and a daily increase of 9.94% [1] - ST Huaxi (002630) with a deviation rate of 4.11% and a daily increase of 4.88% [1] - Wutong Holdings (300292) with a deviation rate of 3.67% and a daily increase of 5.35% [1] - Other stocks that have just crossed their annual moving average with lower deviation rates include: - Jiecheng Co. (300182) with a deviation rate of 0.04% and a daily increase of 1.60% [2] - Ganyue Expressway (600269) with a deviation rate of 0.05% and a daily increase of 0.40% [2] - Guangsha Huaneng (873703) with a deviation rate of 0.06% and a daily increase of 0.96% [2] Trading Activity - The trading turnover rate for notable stocks shows significant activity, with Luopuskin (002333) having a turnover rate of 3.79% and ST Huaxi (002630) at 6.77% [1] - The overall trading environment reflects a mix of high and low turnover rates among stocks that have recently crossed their annual moving averages [1][2]

Group 1 - The medical beauty sector experienced a rise of 3.39% on September 5, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 3812.51, up 1.24%, while the Shenzhen Component Index closed at 12590.56, up 3.89% [1] - Major stocks in the medical beauty sector showed varied performance, with Ai Meike closing at 190.83, up 3.67%, and Huaxi Biological closing at 57.14, up 3.23% [1] Group 2 - The medical beauty sector saw a net inflow of 36.38 million yuan from institutional investors, while retail investors experienced a net outflow of 44.71 million yuan [1] - The trading volume for Ai Meike was 45,900 hands, with a transaction amount of 858 million yuan [1] - The stock performance of other companies in the sector included *ST Meigu, which closed at 3.17, up 0.63%, and Jinbo Biological, which closed at 302.39, down 0.86% [1]

Market Overview - The medical beauty sector experienced a decline of 1.3% on September 4, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Individual Stock Performance - ST Meigu closed at 3.15, with a slight increase of 0.32% and a trading volume of 95,700 shares, amounting to a transaction value of 30.34 million yuan [1] - Huaxi Biological closed at 55.35, down 0.66%, with a trading volume of 46,700 shares and a transaction value of 25.9 million yuan [1] - Aimeike closed at 184.07, down 1.83%, with a trading volume of 41,200 shares and a transaction value of 763 million yuan [1] - Jinbo Biological closed at 305.00, down 3.81%, with a trading volume of 9,732.97 shares and a transaction value of 301 million yuan [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 58.64 million yuan from institutional investors, while retail investors had a net inflow of 24.48 million yuan [1] - The overall capital flow indicates a mixed sentiment, with retail investors showing some interest despite the institutional outflow [1]

奥园美谷科技股份有限公司 关于子公司被申请破产清算的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、子公司被申请破产清算情况概述 申请人襄阳龙马金缘水利工程有限公司以奥园美谷科技股份有限公司（以下 简称"公司"）控股子公司湖北金环绿色纤维有限公司（以下简称"金环绿纤"） 不能清偿到期债务，且明显缺乏清偿能力为由，向襄阳市中级人民法院提出对金 环绿纤破产清算申请。具体内容详见公司于 2025 年 7 月 4 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于子公司被申请破产清算的提示性公告》。 二、子公司被申请破产清算的进展 金环绿纤于近日收到襄阳市中级人民法院送达的编号为（2025）鄂 06 破申 25 号《民事裁定书》，具体内容如下： 证券代码：000615 证券简称：*ST美谷 公告编号：2025-078 董事会 二〇二五年九月一日 准许申请人襄阳龙马金缘水利工程有限公司撤回对被申请人湖北金环绿色 纤维有限公司的破产清算申请。 三、本次事项对公司的影响 申请人已撤回对金环绿纤的破产清算申请，金环绿纤未进入破产清算程序。 该事项 ...

一、本次司法拍卖基本情况 奥园美谷科技股份有限公司（以下简称"公司"）5%以上股东京汉控股集团 有限公司所持公司的 45,373,219 股股票将于 2025 年 8 月 30 日上午 10 时至 2025 年 8 月 31 日上午 10 时止（延时的除外）在"淘宝网"网络司法拍卖平台 （https://sf-item.taobao.com）被上海市浦东新区人民法院公开拍卖。具体内 容详见公司于 2025 年 7 月 18 日在巨潮资讯网（www.cninfo.com.cn）披露的《关 于公司持股 5%以上股东所持部分股份将被司法拍卖的提示性公告》。 二、本次司法拍卖进展情况 2025 年 8 月 29 日 ， 公 司 通 过 " 淘 宝 网 " 网 络 司 法 拍 卖 平 台 （https://sf-item.taobao.com）查询，其显示上述司法拍卖已暂缓。后续拍 卖进展以执行法院出具的法院裁定为准。 三、其他相关事项说明 本次司法拍卖被暂缓，未来是否恢复拍卖尚具有不确定性。本次司法拍卖暂 缓不会对公司治理及日常生产经营造成影响。公司将持续关注该事项的进展，并 将按照有关法律法规及规范性文件的要求及时 ...

Group 1 - The medical beauty sector increased by 0.59% on August 29, with Jinbo Biological leading the gains [1] - The Shanghai Composite Index closed at 3857.93, up 0.37%, while the Shenzhen Component Index closed at 12696.15, up 0.99% [1] - Jinbo Biological's closing price was 312.48, reflecting a rise of 4.41%, with a trading volume of 14,200 lots and a transaction value of 442 million [1] Group 2 - The medical beauty sector saw a net inflow of 60.73 million in main funds, while retail funds experienced a net outflow of 21.81 million [1] - Aimei Ke reported a closing price of 193.98, with a gain of 1.90%, and a trading volume of 48,700 lots, totaling 946 million in transaction value [1] - Huaxi Biological's stock price decreased by 1.00% to 57.20, with a trading volume of 64,200 lots and a transaction value of 36.9 million [1]

Core Viewpoint - *ST Meigu's financial performance for the first half of 2025 shows significant declines in revenue and net profit, indicating increased short-term debt pressure and poor operational efficiency [1]. Financial Performance Summary - Total revenue for the first half of 2025 was 482 million yuan, a decrease of 10.55% year-on-year [1]. - The net profit attributable to shareholders was -83.39 million yuan, down 33.67% compared to the previous year [1]. - In Q2 2025, total revenue was 245 million yuan, reflecting a year-on-year decline of 7.51% [1]. - The net profit for Q2 2025 was -42.21 million yuan, a decrease of 19.33% year-on-year [1]. Key Financial Ratios - Gross margin stood at 20.96%, down 22.43% year-on-year [1]. - Net margin was -20.87%, a significant drop of 87.93% compared to the previous year [1]. - Total expenses (selling, administrative, and financial) amounted to 155 million yuan, accounting for 32.08% of revenue, a decrease of 7.12% year-on-year [1]. - Earnings per share were -0.11 yuan, down 37.5% year-on-year [1]. Cash Flow and Debt Analysis - Cash flow per share was 0.02 yuan, a decline of 81.26% year-on-year [1]. - The current ratio was 0.39, indicating rising short-term debt pressure [1]. - The company had a total of 1.17 billion yuan in cash and cash equivalents, a slight increase of 3.99% year-on-year [1]. - Interest-bearing liabilities were 1.062 billion yuan, down 12.42% year-on-year [1]. Historical Performance Insights - The company's historical return on invested capital (ROIC) has been weak, with a median of 3.76% over the past decade [4]. - The worst year for ROIC was 2022, with a value of -61.52% [4]. - The company has reported losses in 8 out of 28 annual reports since its listing, indicating a challenging financial history [4]. Business Model and Operational Concerns - The company's performance is primarily driven by marketing efforts, necessitating a deeper analysis of the underlying drivers [4]. - Cash flow metrics indicate potential liquidity issues, with cash as a percentage of total assets at only 5.27% and cash to current liabilities at 13.41% [4]. - The financial expense ratio relative to the average operating cash flow over the past three years is concerning, at 54.05% [4].

Group 1 - The medical beauty sector increased by 0.6% on August 28, with Huaxi Biological leading the gains [1] - The Shanghai Composite Index closed at 3843.6, up 1.14%, while the Shenzhen Component Index closed at 12571.37, up 2.25% [1] - The closing prices and performance of key stocks in the medical beauty sector include: - Huaxi Biological: 57.78, up 1.60%, with a trading volume of 82,100 shares and a turnover of 471 million yuan - Aimeike: 190.36, up 0.17%, with a trading volume of 49,700 shares and a turnover of 940.1 million yuan - Jinbo Biological: 299.27, down 1.81%, with a trading volume of 9,644 shares and a turnover of 289 million yuan - *ST Meigu: 3.21, down 3.60%, with a trading volume of 195,800 shares and a turnover of 62.64 million yuan [1] Group 2 - The medical beauty sector experienced a net outflow of 122 million yuan from main funds, while retail funds saw a net inflow of 66.68 million yuan [1] - The fund flow for key stocks shows: - *ST Meigu: net outflow of 5.87 million yuan, down 9.37% - Huaxi Biological: net outflow of 27.85 million yuan, down 5.92% - Aimeike: net outflow of 88.21 million yuan, down 9.39% [2]

证券代码：000615 证券简称：*ST美谷 公告编号：2025-073 经审议，董事会认为：公司《2025 年半年度报告全文》及摘要的编制程序 符合法律、行政法规、中国证监会和深圳证券交易所的相关规定，报告内容真实、 准确、完整地反映了公司的实际情况，不存在虚假记载、误导性陈述或者重大遗 漏。具体内容详见同日刊登于《证券时报》和巨潮资讯网（www.cninfo.com.cn， 下同）的《2025 年半年度报告摘要》及巨潮资讯网的《2025 年半年度报告全文》。 表决结果：9 票同意，0 票反对，0 票弃权。 特此公告。 奥园美谷科技股份有限公司 董事会 二〇二五年八月二十六日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 奥园美谷科技股份有限公司（以下简称"公司"）第十一届董事会第二十五 次会议通知于 2025 年 8 月 16 日上午以电子通讯方式通知公司全体董事，会议于 生主持，会议应到董事 9 人，实到董事 9 人。公司部分监事、高级管理人员列席 了会议。会议的召集、召开程序符合《中华人民共和国公司法》《公司章程》和 《公司董事会议事规则》的有关规定 ...